Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Toripalimab||Phase I||Actionable||In a Phase I trial, Toripalimab (JS001) demonstrated tolerability and preliminary efficacy in patients with advanced malignancies, resulting in an objective response rate of 45.5% (15/33), including complete response in 7/33, partial response in 8/33, and stable disease in 13/33 patients, and median progression-free survival of 7.1 months, with solid tumor patients demonstrating an objective response rate of 22.7% (5/22) and median progression-free survival of 5.7 months (PMID: 32224416; NCT02836834).||32224416|